Nalagenetics develops an end-to-end genetic testing software and services platform, anchored by its proprietary Clinical Decision Support (CDS) portal that processes sequencing and genotyping data and produces guideline-compliant reports. CDS includes modules for pre-test triage, data analysis, reporting, dashboards, and post-test integration for healthcare systems. The company has developed clinical modules for pharmacogenomics, nutrigenomics, and breast cancer risk prediction and plans to build polygenic risk score modules for complex diseases. Nalagenetics was founded in April 2016 out of A*STAR’s Genome Institute of Singapore Innovation Fellow program and is led by CEO Levana Sani. It is active in Indonesia and Singapore, has signed service agreements with over 40 hospital and clinic partners, and is launching services from a new lab location in Singapore. The company raised US$12.6M in a Series A and intends to use proceeds to advance CDS (including whole-genome analysis capabilities), expand provider integrations, and hire bioinformatics, software engineering, and genetics staff.

Total raised

$13M

Funding rounds

1

Latest round

Series A

Latest activity

Mar 2022